Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT06280391
- Locations
- 🇩🇪
Investigational Site Number : 2760005, Bendorf, Germany
🇮🇱Investigational Site Number : 3760008, Ashkelon, Israel
🇵🇱Investigational Site Number : 6160005, Lodz, Lódzkie, Poland
Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 365000
- Registration Number
- NCT06258057
- Locations
- 🇫🇷
Investigational Site, Chilly-Mazarin, France
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 249
- Registration Number
- NCT06241118
- Locations
- 🇮🇱
Investigational Site Number : 3760005, Be'er Sheva, Israel
🇮🇱Investigational Site Number : 3760008, Ramat Gan, Israel
🇮🇱Investigational Site Number : 3760007, Tel Aviv, Israel
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 496
- Registration Number
- NCT06224348
- Locations
- 🇺🇸
Integrative Skin Science and Research- Site Number : 8401275, Sacramento, California, United States
🇺🇸Velocity Clinical Researchâ€" New Orleans- Site Number : 8401155, New Orleans, Louisiana, United States
🇺🇸Equity Medical, LLC- Site Number : 8401239, New York, New York, United States
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 700
- Registration Number
- NCT06208306
- Locations
- 🇺🇸
DL Research Solutions Inc Site Number : 8401033, Miami, Florida, United States
🇺🇸My Community Research Center Site Number : 8402060, Miami, Florida, United States
🇺🇸Phoenix Medical Research - Miami - 24th Street- Site Number : 8402019, Miami, Florida, United States
A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT06192563
- Locations
- 🇮🇹
Investigational Site Number: 002, Bologna, Italy
🇮🇹Investigational Site Number: 006, Brescia, Italy
🇮🇹Investigational Site Number: 004, Firenze, Italy
A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT06193304
- Locations
- 🇺🇸
Covance Clinical Researsh Unit, Evansville, Indiana, United States
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT06191315
- Locations
- 🇺🇸
Phoenix Children's Hospital- Site Number : 8400001, Phoenix, Arizona, United States
🇫🇷Investigational Site Number : 2500001, Lille, France
🇫🇷Investigational Site Number : 2500004, Nice, France
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 10
- Registration Number
- NCT06192576
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT06188325
- Locations
- 🇺🇸
M.D.Covance Clinical Research Unit 1341 W, Dallas, Texas, United States